Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 229

1.

Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels.

Kang SH, Kim DY, Jeon SM, Ahn SH, Park JY, Kim SU, Kim JK, Lee KS, Chon CY, Han KH.

Eur J Gastroenterol Hepatol. 2012 Jul;24(7):849-56. doi: 10.1097/MEG.0b013e3283535c34.

PMID:
22495400
2.

Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.

Kim HS, Park JW, Jang JS, Kim HJ, Shin WG, Kim KH, Lee JH, Kim HY, Jang MK.

J Clin Gastroenterol. 2009 May-Jun;43(5):482-8. doi: 10.1097/MCG.0b013e318182015a.

PMID:
19197197
3.

Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.

Choi JY, Jung SW, Kim HY, Kim M, Kim Y, Kim DG, Oh EJ.

World J Gastroenterol. 2013 Jan 21;19(3):339-46. doi: 10.3748/wjg.v19.i3.339.

4.

Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.

Cui R, Wang B, Ding H, Shen H, Li Y, Chen X.

Chin Med J (Engl). 2002 Jan;115(1):42-5.

PMID:
11930656
5.

PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection.

Kim DY, Paik YH, Ahn SH, Youn YJ, Choi JW, Kim JK, Lee KS, Chon CY, Han KH.

Oncology. 2007;72 Suppl 1:52-7. Epub 2007 Dec 13.

PMID:
18087182
6.

Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma.

Park H, Kim SU, Park JY, Kim DY, Ahn SH, Chon CY, Han KH, Seong J.

Liver Int. 2014 Feb;34(2):313-21. doi: 10.1111/liv.12274. Epub 2013 Jul 29.

PMID:
23895043
7.

Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.

Viggiani V, Palombi S, Gennarini G, D'Ettorre G, De Vito C, Angeloni A, Frati L, Anastasi E.

Scand J Gastroenterol. 2016 Oct;51(10):1257-62. doi: 10.1080/00365521.2016.1183705. Epub 2016 May 26.

PMID:
27227515
9.

Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.

Seo SI, Kim HS, Kim WJ, Shin WG, Kim DJ, Kim KH, Jang MK, Lee JH, Kim JS, Kim HY, Kim DJ, Lee MS, Park CK.

World J Gastroenterol. 2015 Apr 7;21(13):3928-35. doi: 10.3748/wjg.v21.i13.3928.

10.

Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.

Lim TS, Kim DY, Han KH, Kim HS, Shin SH, Jung KS, Kim BK, Kim SU, Park JY, Ahn SH.

Scand J Gastroenterol. 2016 Mar;51(3):344-53. doi: 10.3109/00365521.2015.1082190. Epub 2015 Sep 4.

PMID:
26340708
11.

Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes.

Kasahara A, Hayashi N, Fusamoto H, Kawada Y, Imai Y, Yamamoto H, Hayashi E, Ogihara T, Kamada T.

Dig Dis Sci. 1993 Dec;38(12):2170-6.

PMID:
7505217
12.

Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival.

Nanashima A, Taura N, Abo T, Ichikawa T, Sakamoto I, Nagayasu T, Nakao K.

Dig Dis Sci. 2011 Oct;56(10):3086-100. doi: 10.1007/s10620-011-1796-6. Epub 2011 Jun 25.

PMID:
21706206
13.
14.
15.

Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.

Poté N, Cauchy F, Albuquerque M, Voitot H, Belghiti J, Castera L, Puy H, Bedossa P, Paradis V.

J Hepatol. 2015 Apr;62(4):848-54. doi: 10.1016/j.jhep.2014.11.005. Epub 2014 Nov 11.

PMID:
25450201
16.

[Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].

Kim MJ, Bae KW, Seo PJ, Jeong IK, Kim JH, Lee BH, Bang KT, Kim DW, Song IH.

Korean J Hepatol. 2006 Sep;12(3):404-11. Korean.

PMID:
16998292
17.

Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients.

Abd El Gawad IA, Mossallam GI, Radwan NH, Elzawahry HM, Elhifnawy NM.

J Egypt Natl Canc Inst. 2014 Jun;26(2):79-85. doi: 10.1016/j.jnci.2014.01.001. Epub 2014 Jan 31.

18.

Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study.

Abdel-Razik A, Elhelaly R, Elzehery R, El-Diasty A, Abed S, Elhammady D, Tawfik A.

Eur J Gastroenterol Hepatol. 2016 May;28(5):599-605. doi: 10.1097/MEG.0000000000000569.

PMID:
26741637
19.

Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein.

Suehiro T, Sugimachi K, Matsumata T, Itasaka H, Taketomi A, Maeda T.

Cancer. 1994 May 15;73(10):2464-71.

20.

Usefulness of PIVKA-II After Living-donor Liver Transplantation for Hepatocellular Carcinoma.

Park MS, Lee KW, Kim H, Choi YR, Hong G, Yi NJ, Suh KS.

Transplant Proc. 2017 Jun;49(5):1109-1113. doi: 10.1016/j.transproceed.2017.03.017.

PMID:
28583537

Supplemental Content

Support Center